Zacks' 7 Best Stocks for July, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORTCOM I SPRT
3.75%
UNISYS CORP UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MOUNTA GMCR
3.13%

Align Technology, Inc. (ALGN)

by Zacks Equity Research

May 03, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Align Technology's (ALGN) first-quarter 2012 adjusted EPS of $0.27 surpassed the Zacks Consensus Estimate of $0.22 and the year-ago quarter adjusted EPS of $0.21. Align witnessed balanced sales growth across all its channels, banking on its core product, Invisalign.

Moreover, Cadent's contribution also helped Align to further penetrate the malocclusion market. Align's focus on the international market, especially in Europe, is encouraging. A successful launch of Invisalign G4 is expected to boost the company's revenues further.

Although Align is facing gross margin compression for several quarters, the gradual pick up in patient traffic is expected to add further life to the company's overall performance. Based on the strong growth potential of the company, we upgraded the stock to Outperform.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.